Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy

This study is exploring whether a simplified radiation approach (targeting only the main tumor, without a surrounding safety margin) is safe and effective for patients with advanced non-small cell lung cancer who have already responded well to immunotherapy and chemotherapy. **You may be eligible if...** - You have advanced non-small cell lung cancer (NSCLC) confirmed by biopsy - You have completed at least two cycles of chemotherapy combined with immunotherapy, and your tumor responded (shrank or stabilized) - You are 18–80 years old and in generally good health - Your heart, lungs, kidneys, liver, and blood counts are in acceptable range **You may NOT be eligible if...** - Your cancer progressed (grew) during chemotherapy/immunotherapy - Your tumor has EGFR, ALK, or ROS1 mutations - You have previously had radiation to the chest - You experienced significant immune-related side effects from immunotherapy Talk to your doctor to see if this trial is right for you.